News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
NCODA updated cabozantinib Treatment Support Kit
NCODA/LinkedIn
Apr 20, 2025, 08:05

NCODA updated cabozantinib Treatment Support Kit

NCODA shared a post on LinkedIn:

“As treatment options expand, so do opportunities to offer meaningful support.

With cabozantinib’s new indication for neuroendocrine tumors (NETs), we’ve updated our complimentary Treatment Support Kit (TSK) to better reflect patients’ current needs—preserving core resources while introducing the most relevant new tools.

The refreshed kit includes urea-based skin cream to help manage skin-related side effects, replacing the pill container to better align with the treatment experience. The kit continues to include helpful essentials like loperamide, treatment calendars, diarrhea management education, and more.

Explore all kits and order.”

Cabozantinib cancer fight against cancer Global fight against cancer NCODA NETs neuroendocrine tumors OncoDaily Oncology
Special Coverage
Insight
Jun 2, 2025, 06:19
Martina Zapata Laguado: KN564 maintain benefit on OS in ccRCC
Science
Jun 2, 2025, 06:09
Gerard Mawhinney: 14-year review of the Oxford Spinal Sarcoma Service on primary spinal tumour care
Blog
Jun 2, 2025, 05:45
ABC Global Alliance President, Fatima Cardoso, received the prestigious 2025 Yvonne Award for Lifetime Achievement in Oncology
Oncolibrary
Jun 2, 2025, 05:43
ctDNA Analysis in the Phase 3 NIAGARA Trial: Perioperative Durvalumab with Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
Science
Jun 2, 2025, 05:32
ALNEO Phase II Trial Highlights Promising Role of Perioperative Alectinib in Stage III Resectable ALK-Positive NSCLC
Science
Jun 2, 2025, 05:14
SAVANNAH Trial Highlights Synergistic Effect of Savolitinib and Osimertinib in EGFR-Mutant NSCLC with MET-Mediated Resistance
Science
Jun 2, 2025, 04:58
NATALEE Trial Subgroup Analysis Confirms Ribociclib Benefit Across Age and Menopausal Status in High-Risk HR+/HER2− Early Breast Cancer
Science
Jun 2, 2025, 04:38
T-DXd Demonstrates Promising Activity in Desmoplastic Small Round Cell Tumor (DSRCT)
Oncolibrary
Jun 2, 2025, 04:26
TROPION-Lung02: First-Line Dato-DXd Plus Pembrolizumab With or Without Platinum Chemotherapy Delivers Promising Results in Advanced Non-Small Cell Lung Cancer
Science
Jun 2, 2025, 04:17
NeoSTAR Trial Updates Reports Promising Early Results of Sacituzumab Govitecan Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
Science
Jun 2, 2025, 03:20
KRYSTAL-7 Phase II Trial First-Line Adagrasib Plus Pembrolizumab Delivers Durable Responses Across PD-L1 Levels in KRASG12C-Mutated NSCLC
Oncolibrary
Jun 2, 2025, 02:56
CheckMate 577 Final Results: Adjuvant Nivolumab Sustains Disease-Free Survival Benefit in Resected Esophageal and Gastroesophageal Junction Cancer